menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reviewing a Real Patient’s Experience With Chronic ITP Therapy

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

What are some helpful tips for a patient to start the conversation around selecting a treatment with their practitioner?

  • Sponsored by

  • Overview

    DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. So what do you and your patients need to know about this therapy? Don’t miss out on this compelling episode with Dr Van Doren, Nurse Practitioner Stephanie Johnston, and Tammy, a real Doptelet patient.

    Doptelet is a registered trademark of AkaRx, Inc., a Sobi company.
    Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
    © 2023 Sobi, Inc. - All rights reserved.

    PP-18724 07/23

  • INDICATION

    DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. 

  • IMPORTANT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS

    Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

    Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

    DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

    Serious Adverse Reactions

    Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128). 

    Adverse Reactions

    The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

    Postmarketing Experience

    Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

    These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com  

    To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

    For WAC pricing, visit doptelethcp.com/wac-pricing.

Schedule1 Mar 2024